NeoGenomics (NASDAQ:NGNM) announced an upward revision to its Q1 revenue guidance, now seeing revenues of $14.5 million – $15 million, up from its prior guidance of $13.5 million – $14 million.The company reiterated its Q1 EPS forecast of breakeven to $0.01, and suspended its 2012 guidance, pending the review of implications of middle class tax relief act of 2012.NeoGenomics, Inc. is a research and genetic testing company focused on diseases in women and the early diagnosis of diseases in prenatal infants. The Company is seeking to perform genetic diagnostic procedures for outside clients by establishing a genetic/diagnostic laboratory.SmarTrend is bullish on shares of NeoGenomics and our subscribers were alerted to buy on October 28, 2011 at $1.32. The stock has risen 31.1% since the alert was issued.